No. 2: Gilead Sciences
Industry: Biotechnology
Sales: $4.2 billion
Net Income: $1.6 billionGilead Sciences' (GILD) resounding lead in HIV treatments has landed it on the BusinessWeek 50 list for the fourth year in a row. In 2007, sales at the Foster City (Calif.) company rose 40%, to $4.2 billion, driven largely by Atripla, a drug that combines three potent medicines into one pill. All told, Gilead shareholders enjoyed a 32% return in the 12 months ended Mar. 13. Meanwhile, Chief Executive John Martin has been branching out: A drug to treat pulmonary arterial hypertension was approved in June, and drugs for cystic fibrosis and hepatitis B are awaiting approval by the Food & Drug Administration.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment